Squarepoint’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.77M Buy
8,800
+3,600
+69% +$2.03M 0.01% 1626
2026
Q1
$3.08M Buy
5,200
+4,400
+550% +$2.19M ﹤0.01% 1873
2025
Q4
$390K Buy
800
+200
+33% +$93.1K ﹤0.01% 3411
2025
Q3
$252K Buy
+600
New +$202K ﹤0.01% 3797
2025
Q2
Sell
-1,400
Closed -$432K 5095
2025
Q1
$432K Sell
1,400
-1,000
-42% -$343K ﹤0.01% 3440
2024
Q4
$847K Sell
2,400
-5,300
-69% -$1.95M ﹤0.01% 3220
2024
Q3
$2.76M Sell
7,700
-5,200
-40% -$1.76M ﹤0.01% 1841
2024
Q2
$4.11M Buy
+12,900
New +$3.41M 0.01% 1506
2022
Q4
Sell
-1,300
Closed -$272K 3627
2022
Q3
$272K Buy
1,300
+100
+8% +$22.4K ﹤0.01% 2538
2022
Q2
$283K Buy
+1,200
New +$244K ﹤0.01% 2314

Other funds holding UTHR

Squarepoint's UTHR Position: Q2 2026 in Review

Squarepoint opened a new position in United Therapeutics (UTHR) in Q2 2026: 48,656 shares worth $26.4M. The stake represents 0.03% of the portfolio and ranks #573 among its holdings. This is a return to the name: Squarepoint previously reported a position in UTHR as recently as Q3 2025.

Squarepoint first reported a position in UTHR in Q4 2015 and has held it in 33 quarters since. The position peaked at $40.8M in Q1 2024. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Squarepoint held 48,656 shares of United Therapeutics worth $26.4M as of Q2 2026.
  • United Therapeutics was a new Squarepoint position in Q2 2026.
  • United Therapeutics made up 0.03% of Squarepoint's portfolio in Q2 2026, its #573 holding.
  • Squarepoint first reported a position in United Therapeutics in Q4 2015 and has held it in 33 quarters since.
  • Squarepoint's United Therapeutics position peaked at $40.8M in Q1 2024.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.